Video

Sonal Bhatia from Pfizer: Eliquis Continues to Show Positive Results in Real World Trials

Author(s):

It has been several years since Eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.

It has been several years since Eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.

Sonal Bhatia, MD, from Pfizer discussed the results of this additional research during the American College of Cardiology's annual meeting in Chicago. While Warfarin may still be the preferred treatment method for some patients Bhatia said the results of their studies showed that oral anticoagulants are a viable option for many patients as well.

Related Videos
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
Linda Gillam, MD, MPH | Credit: Atlantic Health System
Linda Gillam, MD, MPH | Credit: Atlantic Health System
Steve Nissen, MD | Credit: Cleveland Clinic
Harpreet Bhatia, MD: Benefits of Universal Screening for Lp(a) Levels
© 2024 MJH Life Sciences

All rights reserved.